AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website...

31, 2009, the Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its...

Aveo said it lost $25.2 million, or 58 cents per share, during the fourth quarter. A year earlier it posted a loss of $10.3 million, or 30 cents per share. Revenue from collaborations with companies like Astellas Pharma and Johnson & Johnson fell to...

At December 31, 2011, XenoPort had cash and cash equivalents and short-term investments of $94.4 million. Since the beginning of the fourth quarter of 2011, XenoPort: Announced that Astellas Pharma Inc. has received marketing approval in Japan for...

The wider loss was attributable to lower revenues as well as increased research and development (R&D) expenses.' Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with...

A group of consumers has filed a class-action lawsuit against Japanese pharmaceutical company Astellas Pharma for presenting what they say is a "sham" petition to the U.S. Food and Drug Administration (FDA) to extend the market exclusivity period for...